First patients sought for new targeted cancer pill trial
NCT ID NCT07456046
Summary
This is the first study in people to test a new oral drug called D3S-003. It is for adults with advanced solid tumors that have a specific genetic change called KRAS G12D and have stopped responding to standard treatments. The main goals are to find a safe dose, see how the body processes the drug, and get an early look at whether it might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KRAS P.G12D are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.